Market Cap: $127.91M
SI
Spruce Biosciences, Inc.
SPRB
NASDAQ (NASDAQ Capital Market)USD
Market Cap: $127.91M
Spruce Biosciences Reevaluates Clinical Strategy Following CAH Trials Outcomes Spruce Biosciences, Inc., a biopharmaceutical company specializing in treatments for neurological and endocrine disorders…
Innovative Approaches in CAH Treatment: Spruce Biosciences' Commitment to Patient Care Spruce Biosciences, Inc., a late-stage biopharmaceutical company, emphasizes its dedication to improving the live…
Spruce Biosciences Advances Treatment Options for Congenital Adrenal Hyperplasia Spruce Biosciences, Inc., a late-stage biopharmaceutical company, is significantly advancing its research and developme…
Innovating Endocrine and Neurological Care: Spruce Biosciences' Commitment to Unmet Needs Spruce Biosciences, Inc., a leading late-stage biopharmaceutical company based in South San Francisco, is at t…
Spruce Biosciences Advances Therapeutic Development for Endocrine Disorders Spruce Biosciences, Inc., a biopharmaceutical company based in South San Francisco, is at the forefront of developing therap…